$CERT

Certara (CERT) Slashes Jobs While Doubling Down On Software Growth

Certara (CERT) reported Q2 2026 results with software revenue up 4% to $48.8M and bookings up 9%, but a net loss of $6.1M due to services decline and higher costs. The company cut 5% of its workforce, saving $13M annually, and reaffirmed full-year revenue guidance of $367M-$382M. Certara also expanded its share repurchase program by $50M.

Original reporting
Published Sep 14, 2026, 7:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 7:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Certara (CERT) Slashes Jobs While Doubling Down On Software Growth — source image
Decision brief

The 30-second read

$CERTNeutralMed
01

Why it matters

The earnings release introduces new financial metrics and guidance, affecting valuation and short‑interest dynamics.

02

Market read

First‑time earnings disclosure for Certara provides fresh data for traders evaluating the stock's near‑term direction.

03

What to watch

The $13M annual cost savings and strengthened balance sheet may improve cash flow sustainability.

Relevance 7/10Novelty 7/10Timing: post‑earnings release

Background

Certara reported Q2 2026 results, highlighting modest software growth, a net loss, and reaffirmed guidance.

Company-level read

Ticker impact

$CERTNeutralMedium confidence
Context

Q2 2026 earnings report showing 4% software revenue growth, $6.1M net loss and reaffirmed 0‑4% revenue guidance.

Expected impact

Potential short‑term downside pressure with a chance of rebound if software bookings accelerate.

Evidence & confidence

The net loss and unchanged guidance weigh on sentiment, while the $13M cost‑savings and $150M total buyback program support a floor.

Market effects

Software and drug‑development services sector may see renewed focus on cost discipline.

U.S. biotech and pharma service firms could experience similar valuation scrutiny.

Limited to companies with comparable software‑driven business models.

Counterpoint

Buy on the back of a growing software pipeline and a sizable buyback program despite short interest.

Key entities

  • Jon Resnick

    CEO who commented on the transformation and reaffirmed guidance.

  • Julien Perrier

    New Chief Commercial Officer tasked with go‑to‑market execution.

Related articles

$CERTMed

Certara, Inc. Q2 2026 Earnings Call Summary

Certara, Inc. reported Q2 2026 updates on its shift to specialist, scientist-led sales and a divestiture of its regulatory and medical writing business. Software revenue is 53% of total, up from 40% two years ago. Full-year revenue guidance is 0% to 4%, with adjusted EBITDA margin guided at 29% to 31%. Net loss from continuing operations was $6.1M. A new $50M share repurchase was authorized.

$CERTMedAI 8/10

Certara (CERT) Q2 2026 Earnings Call Transcript

Certara (CERT) reported Q2 2026 revenue of $93.3 million, up 1% YoY, with software revenue $48.8 million (+4%) and services $44.5 million (-3%). Total bookings were $98.3 million (+1%). Adjusted EBITDA was $26.2 million (28.1% margin). 2026 guidance: revenue $367-$382 million and adjusted EPS $0.31-$0.36. The company completed a divestiture and is integrating AI, and announced NVIDIA partnership.

$CERTMed

Certara Reports Second Quarter 2026 Financial Results

Certara, Inc. (CERT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Certara Reports Second Quarter 2026 Financial Results A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guid

$NKEHighAI 9/10

Why is Nike stock tumbling today?

Nike (NKE) stock dropped 9.6% after reporting mixed Q1 2027 results: earnings beat estimates ($0.48 vs. $0.44) but revenue missed ($11.21B vs. $11.35B). Full-year guidance was significantly lower than expected, with revenue projected to fall in the high single digits and EPS between $1.15 and $1.35. China sales declined 26%, and the company announced a restructuring plan targeting $2.5B in savings by 2031.